Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hypertension than clonidine. Lofexidine was then repurposed for the treatment of opioid withdrawal, as it was seen to be more economical and have fewer side effects than clonidine. Lofexidine was developed by US Woldmeds LLC and it was approved by the FDA on May 16, 2018. It is grouped under the following drug class(es): Alpha-2 agonists and Opioid dependence agents. Its therapeutic use is listed as antidiarrheals and antihypertensives. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Lofexidina and Lofexidinum. Its PubChem CID is 30668.
Lofexidine
| CAS No | 31036-80-3 |
|---|---|
| Molecular Formula | C11H12Cl2N2O |
| Molecular Weight | 259.13 g/mol |
| Synonyms | 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992.
The listed CAS number is 31036-80-3.
The listed molecular formula is C11H12Cl2N2O.
The listed molecular weight is 259.13 g/mol.
2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole.
The source lists Lofexidina and Lofexidinum.